191 related articles for article (PubMed ID: 29708806)
1. Ashitaba (Angelica Keiskei) Exudate Prevents Increases in Plasminogen Activator Inhibitor-1 Induced by Obesity in Tsumura Suzuki Obese Diabetic Mice.
Ohta M; Fujinami A; Oishi K; Kobayashi N; Ohnishi K; Ohkura N
J Diet Suppl; 2019; 16(3):331-344. PubMed ID: 29708806
[TBL] [Abstract][Full Text] [Related]
2. Supplementation with Ashitaba (
Ohkura N; Morimoto-Kamata R; Oishi K; Higo-Yamamoto S; Fujinami A; Inoue KI; Ohta M
J Med Food; 2023 Nov; 26(11):843-848. PubMed ID: 37862040
[No Abstract] [Full Text] [Related]
3. Xanthoangelols isolated from Angelica keiskei inhibit inflammatory-induced plasminogen activator inhibitor 1 (PAI-1) production.
Ohkura N; Nakakuki Y; Taniguchi M; Kanai S; Nakayama A; Ohnishi K; Sakata T; Nohira T; Matsuda J; Baba K; Atsumi G
Biofactors; 2011; 37(6):455-61. PubMed ID: 22038782
[TBL] [Abstract][Full Text] [Related]
4. Ashitaba (Angelica keiskei) extract prevents adiposity in high-fat diet-fed C57BL/6 mice.
Zhang T; Yamashita Y; Yasuda M; Yamamoto N; Ashida H
Food Funct; 2015 Jan; 6(1):135-45. PubMed ID: 25406632
[TBL] [Abstract][Full Text] [Related]
5. Food deprivation induces adipose plasminogen activator inhibitor-1 (PAI-1) expression without accumulation of plasma PAI-1 in genetically obese and diabetic db/db mice.
Oishi K; Ohkura N; Matsuda J; Ishida N
Thromb Haemost; 2007 Oct; 98(4):864-70. PubMed ID: 17938813
[TBL] [Abstract][Full Text] [Related]
6. Anti-platelet effects of chalcones from
Ohkura N; Ohnishi K; Taniguchi M; Nakayama A; Usuba Y; Fujita M; Fujii A; Ishibashi K; Baba K; Atsumi G
Pharmazie; 2016 Nov; 71(11):651-654. PubMed ID: 29441970
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of bone strength and metabolism in type 2 diabetic model Tsumura, Suzuki, Obese Diabetes mice.
Tanaka H; Yamashita T; Yoneda M; Takagi S; Miura T
Bone Rep; 2018 Dec; 9():74-83. PubMed ID: 30094297
[TBL] [Abstract][Full Text] [Related]
8. Tongqiaohuoxue decoction ameliorates obesity-induced inflammation and the prothrombotic state by regulating adiponectin and plasminogen activator inhibitor-1.
Kim SH; Park HS; Hong MJ; Yoo JY; Lee H; Lee JA; Hur J; Kwon DY; Kim MS
J Ethnopharmacol; 2016 Nov; 192():201-209. PubMed ID: 27404230
[TBL] [Abstract][Full Text] [Related]
9. Hypofibrinolytic phenotype in Tsumura Suzuki Obese Diabetes (TSOD) mice unrelated to hyperglycemia.
Ohkura N; Morimoto-Kamata R; Kamikubo Y; Takahashi Y; Oishi K
Drug Discov Ther; 2023 Nov; 17(5):346-350. PubMed ID: 37839864
[TBL] [Abstract][Full Text] [Related]
10. Possible antithrombotic effects of
Ohkura N; Atsumi G; Ohnishi K; Baba K; Taniguchi M
Pharmazie; 2018 Jun; 73(6):315-317. PubMed ID: 29880082
[TBL] [Abstract][Full Text] [Related]
11. Preventive effects of Bofutsushosan on obesity and various metabolic disorders.
Shimada T; Kudo T; Akase T; Aburada M
Biol Pharm Bull; 2008 Jul; 31(7):1362-7. PubMed ID: 18591775
[TBL] [Abstract][Full Text] [Related]
12. A study of cardiovascular function in Tsumura Suzuki obese diabetes, a new model mouse of type 2 diabetes.
Kawada T; Miyata S; Shimada T; Sanzen Y; Ito M; Hemmi C; Iizuka S; Suzuki W; Mihara K; Aburada M; Nakazawa M
Biol Pharm Bull; 2010; 33(6):998-1003. PubMed ID: 20522966
[TBL] [Abstract][Full Text] [Related]
13. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance and low sympathetic nerve activity in the Tsumura Suzuki obese diabetic mouse: a new model of spontaneous type 2 diabetes mellitus and obesity.
Takahashi A; Tabuchi M; Suzuki W; Iizuka S; Nagata M; Ikeya Y; Takeda S; Shimada T; Aburada M
Metabolism; 2006 Dec; 55(12):1664-9. PubMed ID: 17142141
[TBL] [Abstract][Full Text] [Related]
15. Metabolic disease prevention and suppression of fat accumulation by Salacia reticulata.
Shimada T; Nagai E; Harasawa Y; Akase T; Aburada T; Iizuka S; Miyamoto K; Aburada M
J Nat Med; 2010 Jul; 64(3):266-74. PubMed ID: 20225078
[TBL] [Abstract][Full Text] [Related]
16. 4-Nitroquinoline 1-Oxide-Induced Tongue and Esophagus Carcinogenesis in Obese and Diabetic TSOD Mice.
Tanaka T; Kawabata K; Sugie S
World J Oncol; 2017 Aug; 8(4):97-104. PubMed ID: 29147443
[TBL] [Abstract][Full Text] [Related]
17. Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a.
Tang S; Liu W; Pan X; Liu L; Yang Y; Wang D; Xu P; Huang M; Chen Z
Life Sci; 2020 Apr; 246():117404. PubMed ID: 32035128
[TBL] [Abstract][Full Text] [Related]
18. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1.
Skurk T; Hauner H
Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1357-64. PubMed ID: 15356668
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.
Mavri A; Alessi MC; Bastelica D; Geel-Georgelin O; Fina F; Sentocnik JT; Stegnar M; Juhan-Vague I
Diabetologia; 2001 Nov; 44(11):2025-31. PubMed ID: 11719834
[TBL] [Abstract][Full Text] [Related]
20. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.
Alessi MC; Bastelica D; Mavri A; Morange P; Berthet B; Grino M; Juhan-Vague I
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1262-8. PubMed ID: 12750120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
